Dashboard
Manage Tickers

AMPH


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

the-analyst-verdict-amphastar-pharma-in-the-eyes-of-4-experts
The Analyst Verdict: Amphastar Pharma In T...
11/07/2025 11:44:33

needham-maintains-buy-on-amphastar-pharma-lowers-price-target-to-34
Needham Maintains Buy on Amphastar Pharma,...
11/07/2025 10:09:53

Needham analyst Serge Belanger maintains Amphastar Pharma (NASDAQ:AMPH) with a Buy and lowers the price target from $36 to $34.

amphastar-pharma-q3-adj-eps-093-beats-085-estimate-sales-191840m-beat-184728m-estimate
Amphastar Pharma Q3 Adj. EPS $0.93 Beats $...
11/06/2025 21:07:40

Amphastar Pharma (NASDAQ:AMPH) reported quarterly earnings of $0.93 per share which beat the analyst consensus estimate of $0.8...

earnings-scheduled-for-november-6-2025
Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

amphastar-pharmaceuticals-appoints-chengong-as-exclusive-distributor-for-baqsimi-in-greater-china-under-10-year-agreement
Amphastar Pharmaceuticals Appoints Chengon...
10/24/2025 20:28:56

On October 21, 2025 (the "Effective Date") Amphastar Pharmaceuticals, Inc. ("Amphastar"), a wholly-owned subsid...

demystifying-amphastar-pharma-insights-from-4-analyst-reviews
Demystifying Amphastar Pharma: Insights Fr...
10/22/2025 12:01:00

needham-reiterates-buy-on-amphastar-pharma-maintains-36-price-target
Needham Reiterates Buy on Amphastar Pharma...
10/22/2025 10:51:33

Needham analyst Serge Belanger reiterates Amphastar Pharma (NASDAQ:AMPH) with a Buy and maintains $36 price target.

teva-viatris-on-investor-watch-as-white-house-spares-generic-drugs-from-tariffs
Teva, Viatris On Investor Watch As White H...
10/09/2025 13:31:09

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply...

on-sept-15-amphastar-pharmaceuticals-enters-contract-research-agreement-with-hanxin
On Sept 15, Amphastar Pharmaceuticals Ente...
09/18/2025 20:52:31

-SEC Filing

b-of-a-securities-maintains-neutral-on-amphastar-pharma-raises-price-target-to-32
B of A Securities Maintains Neutral on Amp...
08/26/2025 15:23:26

B of A Securities analyst Jason Gerberry maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and raises the price target...

amphastar-secures-fda-nod-for-iron-sucrose-injection-analysts-eye-major-sales-momentum
Amphastar Secures FDA Nod For Iron Sucrose...
08/12/2025 17:38:58

FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2...

needham-upgrades-amphastar-pharma-to-buy-announces-36-price-target
Needham Upgrades Amphastar Pharma to Buy, ...
08/12/2025 12:16:47

Needham analyst Serge Belanger upgrades Amphastar Pharma (NASDAQ:AMPH) from Hold to Buy and announces $36 price target.

amphastar-pharmaceuticals-signs-453m-exclusive-licensing-deal-with-nanjing-anji-for-three-proprietary-peptides-in-oncology-and-ophthalmology
Amphastar Pharmaceuticals Signs $453M Excl...
08/12/2025 10:03:39

the-fda-approved-amphastar-pharmaceuticals-abbreviated-new-drug-application-for-iron-sucrose-injection-in-single-dose-vials-indicated-for-iron-deficiency-anemia-in-patients-with-chronic-kidney-disease
The FDA Approved Amphastar Pharmaceuticals...
08/11/2025 10:04:06

According to IQVIA, the U.S. sales for Venofer® were approximately $513 million for the 12 months ended June 30, 2025. Pipeline...

piper-sandler-maintains-neutral-on-amphastar-pharma-lowers-price-target-to-25
Piper Sandler Maintains Neutral on Amphast...
08/08/2025 11:25:43

Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target fro...

amphastar-pharma-q2-adj-eps-085-beats-076-estimate-sales-174414m-beat-174249m-estimate
Amphastar Pharma Q2 Adj. EPS $0.85 Beats $...
08/07/2025 20:09:32

Amphastar Pharma (NASDAQ:AMPH) reported quarterly earnings of $0.85 per share which beat the analyst consensus estimate of $0.7...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

this-target-analyst-turns-bearish-here-are-top-5-downgrades-for-monday
This Target Analyst Turns Bearish; Here Ar...
05/12/2025 13:26:47

jp-morgan-downgrades-amphastar-pharma-to-neutral-lowers-price-target-to-30
JP Morgan Downgrades Amphastar Pharma to N...
05/12/2025 12:23:03

JP Morgan analyst Ekaterina Knyazkova downgrades Amphastar Pharma (NASDAQ:AMPH) from Overweight to Neutral and lowers the pr...

wells-fargo-maintains-overweight-on-amphastar-pharma-lowers-price-target-to-35
Wells Fargo Maintains Overweight on Amphas...
05/08/2025 13:21:39

Wells Fargo analyst Cerena Chen maintains Amphastar Pharma (NASDAQ:AMPH) with a Overweight and lowers the price target from ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION